The Dawn of the Brain-Computer Interface Era: Policy Leadership, Clinical Validation, and the Road Ahead | China Innovative Healthcare Assets Salon – Episode 3

Brain-computer interface (BCI) technology is entering a critical phase of transitioning from the laboratory to clinical practice and from concept to industry. Invasive, semi-invasive, and non-invasive approaches are developing in parallel, achieving remarkable clinical progress in areas such as motor function restoration for patients with paralysis and communication assistance for those with amyotrophic lateral sclerosis (ALS), thereby laying a solid foundation for practical implementation.

At the policy level, brain-computer interfaces (BCIs) have been designated as a key focus area for future industries, with successive releases of supportive policies and standardized regulations creating a favorable environment for the sector’s healthy development. On the capital front, according to incomplete statistics from the VCBeat Orange Database, China’s BCI sector had completed 24 financing rounds by December 2025, with total funding exceeding RMB 5 billion.

Against this backdrop, on Monday, February 9, at 15:00, VCBeat and Wei Jieyao jointly hosted the “China Innovative Medical Assets Lounge” Insight RelativityEpisode 3, featuringHe Wenbin, Co-Chief Healthcare Analyst at Guotai Haitong Securities Research InstituteAroundYear One of Brain-Computer Interfaces: Policy Leads the Way, Clinical Validation Underway, and the Future ArrivesTopic Sharing: Deconstructing Opportunities and Challenges in the Sector, Exploring the New Landscape of the “Year One of Brain-Computer Interfaces”